Trial | NCT00135863  Report issue

Title

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis
Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Terminated

  • Intervention/Treatment

    tinzaparin ...

  • Study Participants

    36
Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R) (Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. Active medication, as well as placebo, was added for three months separated by a one month washout period. At the beginning and end of each treatment period peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed. We, the researchers at Ribe County Hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.
Study Started
May 31
2004
Study Completion
May 31
2005
Last Update
May 21
2015
Estimate

Drug tinzaparin

Criteria 

Inclusion Criteria:

End stage renal disease
Peritoneal dialysis without complication for minimum of three months
18 years or above
Informed consent

Exclusion Criteria:

Known coagulatory defects including anticoagulation therapy
Known bleeding tendency
Peritonitis within two months prior to inclusion
Pregnancy
Breast feeding
Active infection
Non-informed consent
Allergy to heparin or prior heparin induced thrombocytopenia
No Results Posted